Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Pharmacological interventions in mild cognitive impairment and dementia 

Pharmacological interventions in mild cognitive impairment and dementia
Chapter:
Pharmacological interventions in mild cognitive impairment and dementia
Author(s):

Jacques Hugon

and Claire Paquet

DOI:
10.1093/med/9780198701590.003.0128
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 15 June 2021

Alzheimer’s disease (AD) and other dementias are a major public health concern in many countries because of population ageing. The aetiologic causes of most of the dementias are unknown and recent pharmacological interventions are based on hypotheses such as the ‘amyloid cascade hypothesis’ for AD. Drugs can be divided between symptomatic treatments and disease-modifying drugs. So far regulatory authorities have only approved choline esterase inhibitors (ChEIs) and memantine in AD. It is postulated that the brain lesions in this disease occur 10–15 years before the first clinical signs. New clinical trials are now also including patients with mild cognitive impairment, a stage which often precedes dementia. Primary and secondary outcomes incorporate neuropsychological evaluations but also biomarker assessments such as positon emission tomography (PET) imaging and cerebrospinal fluid (CSF) measurements. This chapter focuses on current available therapies and recent or ongoing clinical trials in mild cognitive impairment and dementias.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.